Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SAN DIEGO, Aug. 01, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its second quarter financial and operating results after the close of U.S. financial markets on Tuesday, August 8, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | August 8, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 63640830 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
